Abstract: Pyrmidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.

Abstract: A compound represented by the general formula (I) or a salt thereof, wherein R represents a group represented by the following formula (A), (B) or (C) wherein R1 and R2 independently represent a C1-6 alkyl group, R3 represents an amino group, a mono(C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group or a C1-6 alkoxy group and X-represents an anion, and n represents an integer of 2 to 5. The compound or a salt is useful as a ligand of inositol-1,4,5-trisphosphate (IP3) receptor.

Abstract: A low monomer 1:1-monoadduct from a diisocyanate and a hydroxy(meth)acrylate with a free diisocyanate content of less than 0.7% by weight and a free NCO content of 10.4-16.4% by weight can be used as a starting material for an acrylic or NCO functionalized crosslinker; a bonding agent for coatings and adhesives; and a linker for solid-phase synthesis of oligo-nucleotides, polynucleotides or peptides. The monoadduct is obtained by converting 5-20 mol diisocyanate with 1 mol hydroxy(meth)acrylate at a temperature of 40-120° C. in the presence of at least one inhibitor; subsequently separating a non-converted diisocyanate from a reaction product by short-path distillation at 80-220° C./0.1-10 mbar; feeding air, nitrogen monoxide or oxygen or a mixture containing (a) air, oxygen or nitrogen monoxide and (b) a proportion of 1-90% by volume of carbon dioxide, nitrogen, an inert gas or a mixture thereof through a reaction apparatus.

Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.